OvaScience Inc. (NASDAQ:OVAS)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued to investors on Sunday.
OVAS has been the topic of several other reports. Zacks Investment Research lowered OvaScience from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 2nd. Credit Suisse Group AG reiterated a “sell” rating on shares of OvaScience in a report on Tuesday, July 12th. JMP Securities reiterated a “neutral” rating on shares of OvaScience in a report on Wednesday, August 10th. Finally, JPMorgan Chase & Co. dropped their target price on OvaScience from $9.00 to $8.00 and set a “neutral” rating on the stock in a report on Friday, August 5th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. OvaScience has an average rating of “Hold” and an average price target of $8.52.
Shares of OvaScience (NASDAQ:OVAS) traded down 3.33% on Friday, hitting $3.77. The stock had a trading volume of 296,674 shares. The stock’s market capitalization is $134.24 billion. OvaScience has a one year low of $3.39 and a one year high of $11.66. The firm’s 50 day moving average is $4.97 and its 200-day moving average is $6.05.
OvaScience (NASDAQ:OVAS) last posted its earnings results on Thursday, November 3rd. The company reported ($0.54) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.62) by $0.08. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.25 million. OvaScience had a negative return on equity of 62.66% and a negative net margin of 11,642.67%. The company’s revenue for the quarter was down 73.3% on a year-over-year basis. During the same period in the previous year, the company posted ($0.66) earnings per share. Equities research analysts expect that OvaScience will post ($2.51) earnings per share for the current fiscal year.
Institutional investors have recently bought and sold shares of the stock. Janus Capital Management increased its stake in shares of OvaScience by 2.9% in the third quarter. Janus Capital Management now owns 3,846,294 shares of the company’s stock worth $32,655,000 after buying an additional 110,073 shares in the last quarter. DIAM Co. Ltd. increased its stake in shares of OvaScience by 0.8% in the fourth quarter. DIAM Co. Ltd. now owns 296,434 shares of the company’s stock worth $2,970,000 after buying an additional 2,209 shares in the last quarter. AWM Investment Company Inc. increased its stake in shares of OvaScience by 1.2% in the fourth quarter. AWM Investment Company Inc. now owns 116,352 shares of the company’s stock worth $1,137,000 after buying an additional 1,352 shares in the last quarter. BlackRock Group LTD increased its stake in shares of OvaScience by 403.5% in the first quarter. BlackRock Group LTD now owns 22,717 shares of the company’s stock worth $216,000 after buying an additional 18,205 shares in the last quarter. Finally, BlackRock Fund Advisors increased its stake in shares of OvaScience by 1.1% in the first quarter. BlackRock Fund Advisors now owns 967,190 shares of the company’s stock worth $9,179,000 after buying an additional 10,277 shares in the last quarter. 79.37% of the stock is currently owned by institutional investors.
OvaScience Company Profile